These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20124218)

  • 1. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
    Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
    Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.
    Stoneham S; Lennard L; Coen P; Lilleyman J; Saha V
    Br J Haematol; 2003 Oct; 123(1):100-2. PubMed ID: 14510948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
    Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
    Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy.
    Broxson EH; Dole M; Wong R; Laya BF; Stork L
    Pediatr Blood Cancer; 2005 Mar; 44(3):226-31. PubMed ID: 15503293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
    Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
    Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
    Toksvang LN; Als-Nielsen B; Bacon C; Bertasiute R; Duarte X; Escherich G; Helgadottir EA; Johannsdottir IR; Jónsson ÓG; Kozlowski P; Langenskjöld C; Lepik K; Niinimäki R; Overgaard UM; Punab M; Räty R; Segers H; van der Sluis I; Smith OP; Strullu M; Vaitkevičienė G; Wik HS; Heyman M; Schmiegelow K
    BMC Cancer; 2022 May; 22(1):483. PubMed ID: 35501736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
    Vora A; Mitchell CD; Lennard L; Eden TO; Kinsey SE; Lilleyman J; Richards SM; ;
    Lancet; 2006 Oct; 368(9544):1339-48. PubMed ID: 17046466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
    Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
    Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
    Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
    Bostrom BC; Sensel MR; Sather HN; Gaynon PS; La MK; Johnston K; Erdmann GR; Gold S; Heerema NA; Hutchinson RJ; Provisor AJ; Trigg ME;
    Blood; 2003 May; 101(10):3809-17. PubMed ID: 12531809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
    J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
    Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
    Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
    Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
    J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
    Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
    Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.
    Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H
    Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
    Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
    J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
    Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
    J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.